Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/180482
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | PDGF restores the defective phenotype of adipose-derived mesenchymal stromal cells from diabetic patients |
Autor: | Capilla-González, Vivian CSIC ORCID; López-Beas, Javier CSIC; Escacena, Natalia CSIC; Aguilera, Yolanda CSIC ORCID ; Cuesta, Antonio de la; Ruiz-Salmerón, Rafael; Martín, Franz CSIC ORCID; Hmadcha, Abdelkrim CSIC ORCID; Soria Escoms, Bernat CSIC ORCID | Palabras clave: | Adipose-derived mesenchymal stromal cells PDGF Thrombotic state Migration Proliferation Homing Critical limb ischemia Diabetes |
Fecha de publicación: | 7-nov-2018 | Editor: | Elsevier | Citación: | Molecular Therapy 26(11): 2696-2709 (2018) | Resumen: | Diabetes is a chronic metabolic disorder that affects 415 million people worldwide. This pathology is often associated with long-term complications, such as critical limb ischemia (CLI), which increases the risk of limb loss and mortality. Mesenchymal stromal cells (MSCs) represent a promising option for the treatment of diabetes complications. Although MSCs are widely used in autologous cell-based therapy, their effects may be influenced by the constant crosstalk between the graft and the host, which could affect the MSC fate potential. In this context, we previously reported that MSCs derived from diabetic patients with CLI have a defective phenotype that manifests as reduced fibrinolytic activity, thereby enhancing the thrombotic risk and compromising patient safety. Here, we found that MSCs derived from diabetic patients with CLI not only exhibit a prothrombotic profile but also have altered multi-differentiation potential, reduced proliferation, and inhibited migration and homing to sites of inflammation. We further demonstrated that this aberrant cell phenotype is reversed by the platelet-derived growth factor (PDGF) BB, indicating that PDGF signaling is a key regulator of MSC functionality. These findings provide an attractive approach to improve the therapeutic efficacy of MSCs in autologous therapy for diabetic patients. | Versión del editor: | https://doi.org/10.1016/j.ymthe.2018.08.011 | URI: | http://hdl.handle.net/10261/180482 | DOI: | 10.1016/j.ymthe.2018.08.011 | ISSN: | 1525-0016 | E-ISSN: | 1525-0024 |
Aparece en las colecciones: | (CABIMER) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
33
checked on 13-mar-2024
SCOPUSTM
Citations
43
checked on 15-abr-2024
WEB OF SCIENCETM
Citations
42
checked on 23-feb-2024
Page view(s)
558
checked on 22-abr-2024
Download(s)
26
checked on 22-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.